UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s
Telephone Number, Including Area Code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On November 16, 2026, HCW Biologics Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information set forth in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press release dated November 16, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| HCW BIOLOGICS INC. | ||
| Date: November 16, 2026 | By: | /s/ Hing C. Wong |
| Hing C. Wong | ||
| Founder and Chief Executive Officer | ||
Exhibit 99.1

HCW Biologics Reports Third Quarter 2026
Business and Clinical Development Highlights and Financial Results
Miramar,
FL – November
The
Company featured two of its preclinical, non-Fc TRBC molecules at the 41st
The
submission for the Company’s second-generation, tetravalent immune checkpoint inhibitor, HCW11-040, was recognized by
In
the three months ended September 30, 2026, the Company activated an additional clinical site to participate in the HCW9302 Phase 1 clinical
study in alopecia areata and continued patient enrollment and treatment in the third dose cohort (i.e., eight (8) micrograms/kg body
weight). In patients treated to date,
Dr. Hing C. Wong, the Company’s Founder
and Chief Executive Officer, stated, “Progress continues steadily for our clinical study evaluating HCW9302 in alopecia
areata, and we are encouraged by results in humans that are consistent with our preclinical studies. We have the support of strong
clinical sites who share our passion for developing breakthrough immunotherapeutics. With the addition of a third clinical site, we
are hopeful that patient enrollment will maintain a good momentum as we come to the end of the Phase 1
Business and Clinical Development Highlights
In
the nine months ended September 30, 2026, the Company raised $8.6 million of equity financing, which allowed it to
As
a result of discussions at a recent Type B meeting with the U.S. Food and Drug Administration (“FDA”), the FDA provided the
Company with clear guidance for the next steps to prepare its IND application to support a first-in-human clinical study to evaluate
HCW11-018b in solid tumors, which the Company intends to file in the first half of 2027. In support of potential upcoming clinical trials,
the Company has initiated cGMP manufacturing
Third Quarter 2026 Financial Results
Revenues:
Revenues for the three months ended September 30, 2025 and 2026 were $15,606 and $55,463, respectively. Revenues in the nine months
ended September 30, 2025 and 2026 were $27,222 and $6.7 million, respectively. In the
Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2025 and 2026 were $1.4 million and $1.2 million, respectively, a decrease of $161,670, or 12%. The decrease was primarily due to decreases in salaries, benefits and related taxes and preclinical expenses. R&D expenses for the nine months ended September 30, 2025 and 2026 were $4.1 million and $3.7 million, respectively, a decrease of $405,905, or 10%. The decrease was primarily due to a decline in manufacturing and materials expenses, partially offset by increases in taxes and salaries, benefits and related expenses.
General
and administrative (G&A) expenses: G&A expenses for the three months ended September 30, 2025 and 2026 were $1.8 million
and $1.4 million, respectively, a decrease of $518,608, or 28%. The decrease was primarily attributable to decreases in stock-based compensation
expense and a decline
Legal expenses (recoveries), net: Legal expenses and recoveries, net represent the legal fees that the Company incurred for an Arbitration, net of insurance recoveries. In the nine months ended September 30, 2025, the Company received a $2.0 million insurance recovery, partially offset by $409,055 of legal expenses. In the nine months ended September 30, 2026, there were expenses of $14,483. The Company anticipates it will continue to incur some expenses for the costs of remaining in compliance with the terms of the Settlement and Release Agreement from the Arbitration, primarily due to requirements for patents which are necessary to protect the Company’s exclusive, worldwide intellectual property rights held in perpetuity.
Nonoperating changes impacting net income (loss): In the three months ended September 30, 2025, the was a decrease in fair value of $966,284 related to the change in the fair value of the Company’s shares in AlloTera Therapeutics and the related contingent liability, and a loss of $182,146 on the sale of put shares through the Company’s Standby Equity Purchase Agreement. In the three months ended September 30, 2026, there was a $494,683 loss on the return of equipment.
In the nine months ended September 30, 2025, there was an increase in fair value of $782,404 related to the change in fair value of the Company’s shares in AlloTera Therapeutics and the related contingent liability, a loss of $182,146 on the sale of put shares through the Company’s Standby Equity Purchase Agreement. In the nine months ended September 30, 2026, there was a $1.8 million nonoperating loss, primarily consisting of a $1.8 million decrease in the fair value of a warrant liability, which was reclassified to equity in this period.
Net
loss: Net loss for the three months ended September 30, 2025 and 2026 was $4.6 million and $3.2 million, respectively. Net loss for
the nine months ended September 30, 2025 and 2026, was $8.7 million and
Financial Guidance
As of September 30, 2026, the Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the issuance date of the audited financial statements, without additional funding or financial support. We considered future elements of our financing plan, but we cannot be assured that we will continue to have success with remaining elements of our plan.
On
June 26, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company
About HCW Biologics
HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. HCW Biologics is the leader in creation of multi-valent immunotherapeutics with a unique protein-based scaffold, without the antibody Fc domain. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation —and in doing so, improve patients’ quality of life and possibly extend longevity. A key aspect of the Company’s clinical development and financing strategy is to focus on its business development programs, including its commercial-ready reagents to be used in the production of immunotherapeutics for cancer and infectious diseases. To date, the Company has entered into two licensing agreements in which it has licensed exclusive, worldwide rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/
Forward Looking Statements
Statements
in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These
statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,”
“believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,”
“forecast” or other similar words. Forward-looking statements are based on the Company’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are difficult to predict, including timing and efficacy in human clinical
trial data for HCW9302,
Company Contact:
Rebecca Byam
CFO
HCW Biologics Inc.
rebeccabyam@hcwbiologics.com
HCW Biologics Inc.
Condensed Statements of Operations
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2026 | 2025 | 2026 | |||||||||||||
| Revenues: | ||||||||||||||||
| Revenues | $ | 15,606 | $ | 55,463 | $ | 27,222 | $ | 6,734,032 | ||||||||
| Cost of revenues | (12,485 | ) | (27,345 | ) | (21,777 | ) | (267,871 | ) | ||||||||
| Gross Profit | 3,121 | 28,118 | 5,445 | 6,466,161 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 1,404,247 | 1,242,577 | 4,109,782 | 3,703,877 | ||||||||||||
| General and administrative | 1,884,994 | 1,366,386 | 6,187,296 | 5,070,038 | ||||||||||||
| Legal expenses (recoveries), net | 6,006 | 9,058 | (1,590,945 | ) | 14,583 | |||||||||||
| Indirect tax expense | - | - | - | 198,146 | ||||||||||||
| Total operating expenses | 3,295,247 | 2,618,021 | 8,706,133 | 8,986,644 | ||||||||||||
| Operating loss | (3,292,126 | ) | (2,589,903 | ) | (8,700,688 | ) | (2,520,483 | ) | ||||||||
| Interest expense | (127,070 | ) | (141,797 | ) | (632,923 | ) | (351,612 | ) | ||||||||
| Change in fair value of contingent liability, net | 1,055,825 | - | (692,531 | ) | - | |||||||||||
| Change in fair value of investment, net | (2,022,109 | ) | - | 1,474,935 | - | |||||||||||
| Change in fair value of warrant liability | - | - | - | (1,775,992 | ) | |||||||||||
| Loss on sale of put shares | (182,146 | ) | - | (182,146 | ) | - | ||||||||||
| Loss on return of equipment | - | (494,683 | ) | - | (494,683 | ) | ||||||||||
| Gain on extinguishment of liability | - | - | - | 483,383 | ||||||||||||
| Other income, net | 13,290 | 3,554 | 54,412 | 19,992 | ||||||||||||
| Net loss before income taxes | (4,554,336 | ) | (3,222,829 | ) | (8,678,941 | ) | (4,639,395 | ) | ||||||||
| Income tax expense | - | - | - | (330,186 | ) | |||||||||||
| Net loss | $ | (4,554,336 | ) | $ | (3,222,829 | ) | $ | (8,678,941 | ) | $ | (4,969,581 | ) | ||||
| Equity dividend to investor | - | (2,718,837 | ) | (10,153,799 | ) | (14,361,951 | ) | |||||||||
| Net loss attributable to Common Stockholders | $ | (4,554,336 | ) | $ | (5,941,666 | ) | $ | (18,832,740 | ) | $ | (19,331,532 | ) | ||||
| Net loss per share, basic and diluted | $ | (12.09 | ) | $ | (2.83 | ) | $ | (68.02 | ) | $ | (13.35 | ) | ||||
| Weighted average shares outstanding, basic and diluted | 376,678 | 2,101,872 | 276,889 | 1,448,485 | ||||||||||||
HCW Biologics Inc.
Condensed Balance Sheets
| December 31, | September 30, | |||||||
| 2025 | 2026 | |||||||
| Unaudited | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 1,952,464 | $ | 955,458 | ||||
| Accounts receivable, net | 32,175 | - | ||||||
| Prepaid expenses | 222,156 | 239,998 | ||||||
| Other current assets | 77,564 | 85,202 | ||||||
| Total current assets | 2,284,359 | 1,280,658 | ||||||
| Investments | 1,326,329 | 4,854,028 | ||||||
| Property, plant and equipment, net | 20,880,849 | 18,963,834 | ||||||
| Other assets | 28,476 | 28,476 | ||||||
| Total assets | $ | 24,520,013 | $ | 25,126,996 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Liabilities | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 13,143,394 | $ | 9,435,785 | ||||
| Accrued liabilities and other current liabilities | 1,110,104 | 1,046,440 | ||||||
| Short-term debt, net | 6,809,215 | 6,831,899 | ||||||
| Deferred revenue | — | 297,101 | ||||||
| Total current liabilities | 21,062,713 | 17,611,225 | ||||||
| Contingent liability - related party | 692,531 | 692,531 | ||||||
| Total liabilities | 21,755,244 | 18,303,756 | ||||||
| Commitments and contingencies (Note 12) | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock: | ||||||||
| Common, $0.0001 par value; 250,000,000 shares authorized and 546,635 shares issued at December 31, 2025; 250,000,000 shares authorized and 2,236,324 shares issued at September 30, 2026 | 55 | 223 | ||||||
| Additional paid-in capital | 111,280,560 | |||||||
| Accumulated deficit | (108,515,846 | ) | (113,485,426 | ) | ||||
| Total stockholders’ equity | 2,764,769 | |||||||
| Total liabilities and stockholders’ equity | $ | 24,520,013 | $ | |||||